Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1841-1850

  Wang, Ya Feng ^a,b   Kunda, Patricia E ^c   Lin, Jian Wei ^c   Wang, Han ^c   Chen, Xue Mei ^c   Liu, Qiu Ling ^b   Liu, Tao ^c  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c Poten Biomedical Institute for Cancer Immunotherapy   (China)

Author keywords

Carboplatin resistant; Chemical therapy; Cytokine induced killer cells; Dendritic cells; Immunotherapy; Retinoblastoma

Indexed keywords

CARBOPLATIN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL DIFFERENTIATION; CELL LEVEL; CELL PROLIFERATION; CELL SPECIFICITY; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; DENDRITIC CELL; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; RETINOBLASTOMA; TUMOR ANTIGEN LOADED DENDRITIC CELL;

ANTIGENS, NEOPLASM; CARBOPLATIN; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-10; INTERLEUKIN-6; RETINAL CONE PHOTORECEPTOR CELLS; RETINOBLASTOMA;

EID: 84876232313     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2315     Document Type: Article

References (51)

1. Dimaras H, Kimani K, Dimba EA, et al: Retinoblastoma. Lancet 379: 1436-1446, 2012.
2. Bai S, Ren R, Li B, et al: Delay in the diagnosis of retinoblastoma in China. Acta Ophthalmol 89: e72-74, 2011.
3. MacCarthy A, Draper GJ, Steliarova-Foucher E and Kingston JE: Retinoblastoma incidence and survival in European children (1978-1997). Report from the Automated Childhood Cancer Information System project. Eur J Cancer 42: 2092-2102, 2006. (Pubitemid 44224062)
4. Gallie BL, Zhao J, Vandezande K, White A and Chan HS: Global issues and opportunities for optimized retinoblastoma care. Pediatr Blood Cancer 49: 1083-1090, 2007. (Pubitemid 350035128)
5. Houston SK, Murray TG, Wolfe SQ and Fernandes CE: Current update on retinoblastoma. Int Ophthalmol Clin 51: 77-91, 2011.
6. Radhakrishnan V, Kashyap S, Pushker N, et al: Outcome, pathologic findings and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology 119: 1470-1477, 2012.
7. Pica A, Moeckli R, Balmer A, et al: Preliminary experience in treatment of papillary and macular retinoblastoma: evaluation of local control and local complications after treatment with linear accelerator-based stereotactic radiotherapy with micromultileaf collimator as second-line or salvage treatment after chemotherapy. Int J Radiat Oncol Biol Phys 81: 1380-1386, 2011.
8. Wilson MW, Fraga CH, Rodriguez-Galindo C, Hagedorn N, Leggas ML and Stewart C: Expression of the multi-drug resistance proteins and the pregnane X receptor in treated and untreated retinoblastoma. Curr Eye Res 34: 386-394, 2009.
9. Rutella S, Iudicone P, Bonanno G, et al: Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy 14: 841-850, 2012.
10. Campoli M, Ferris R, Ferrone S and Wang X: Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 16: 11-20, 2010.
11. Leffers N, Daemen T, Helfrich W, et al: Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev CD007287, 2010.
12. Palucka K, Ueno H, Fay J and Banchereau J: Dendritic cells and immunity against cancer. J Intern Med 269: 64-73, 2011.
13. Cella M, Sallusto F and Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9: 10-16, 1997. (Pubitemid 27095893)
14. de Vleeschouwer S, Rapp M, Sorg RV, et al: Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery 59: 988-999, 2006. (Pubitemid 44852063)
15. Schnurr M, Galambos P, Scholz C, et al: Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 61: 6445-6450, 2001. (Pubitemid 32783250)
16. Wu YG, Wu GZ, Wang L, Zhang YY, Li Z and Li DC: Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo. Med Oncol 27: 736-742, 2010.
17. Mesiano G, Todorovic M, Gammaitoni L, et al: Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 12: 673-684, 2012.
18. Shi L, Zhou Q, Wu J, et al: Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 61: 2251-2259, 2012.
19. Zhang J, Zhu L, Wei J, et al: The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. J Cancer Res Clin Oncol 138: 1057-1062, 2012.
20. Zhan HL, Gao X, Pu XY, et al: A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl) 125: 3771-3777, 2012.
21. Yang L, Ren B, Li H, et al: Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother: Jun 29, 2012 (Epub ahead of print).
22. Zhong R, Teng J, Han B and Zhong H: Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 60: 1497-1502, 2011.
23. Komada Y, Zhang SL, Zhou YW, et al: Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy. Cancer Immunol Immunother 35: 271-276, 1992.
24. Mackall CL: T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 18: 10-18, 2000.
25. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21: 1673-1679, 1993. (Pubitemid 24223014)
26. Pletinckx K, Stijlemans B, Pavlovic V, et al: Similar inflammatory DC maturation signatures induced by TNF or Trypanosoma brucei antigens instruct default Th2-cell responses. Eur J Immunol 41: 3479-3494, 2011.
27. Puri RK and Leland P: Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo. Lymphokine Cytokine Res 11: 133-139, 1992.
28. Buelens C, Willems F, Delvaux A, et al: Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 25: 2668-2672, 1995.
29. Kulkarni AB, Mullbacher A and Blanden RV: Functional analysis of macrophages, B cells and splenic dendritic cells as antigen-presenting cells in West Nile virus-specific murine T lymphocyte proliferation. Immunol Cell Biol 69: 71-80, 1991.
30. Hasel T, Yoshimura R, Wada S and Chargui J: Dendritic cells, generated in vitro, are immunocompetent and very useful in the induction of specific cytotoxic T lymphocyte activity. Transplant Proc 33: 3814-3815, 2001. (Pubitemid 34042790)
31. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696, 1994.
32. Wang FS, Liu MX, Zhang B, et al: Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 8: 464-468, 2002. (Pubitemid 34692743)
33. Ma Y, Zhang Z, Tang L, et al: Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 14: 483-493, 2012.
34. + cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 7: 216-222, 2001.
35. Baker J, Verneris MR, Ito M, Shizuru JA and Negrin RS: Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 97: 2923-2931, 2001.
36. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149, 1991.
37. Leemhuis T, Wells S, Scheffold C, Edinger M and Negrin RS: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11: 181-187, 2005. (Pubitemid 40287916)
38. Zhang YS, Yuan FJ, Jia GF, et al: CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 11: 3339-3345, 2005.
39. Jiang JT, Shen YP, Wu CP, et al: Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 16: 6155-6162, 2010.
40. Chen J, Huang X, Huang G, Chen Y, Chen L and Song H: Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother Radiopharm 27: 210-220, 2012.
41. Su X, Zhang L, Jin L, et al: Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer Biother Radiopharm 25: 465-470, 2010.
42. + cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 77: 175-179, 2003.
43. Verneris MR, Arshi A, Edinger M, et al: Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res 11: 4561-4570, 2005. (Pubitemid 40825647)
44. Wang QJ, Wang H, Pan K, et al: Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK) and semi-allogeneic DC-CIK. Chin J Cancer 29: 641-648, 2010.
45. Shi SB, Ma TH, Li CH and Tang XY: Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 98: 314-319, 2012.
46. Yang XJ, Huang JA, Lei W, Zhu YB and Zhang XG: Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo. Ai Zheng 25: 1329-1333, 2006.
47. Tan G, Zhang X, Feng H, Luo H and Wang Z: The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide. Clin Dev Immunol 2011: 649359, 2011.
48. Coughlin CM, Vance BA, Grupp SA and Vonderheide RH: RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103: 2046-2054, 2004. (Pubitemid 38326219)
49. Yufeng D, Guocheng Z, Dongliang X, et al: Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-cell response against pediatric nasopharyngeal carcinoma in vitro. Med Oncol 26: 78-85, 2009.
50. Holsti MA and Raulet DH: IL-6 and IL-1 synergize to stimulate IL-2 production and proliferation of peripheral T cells. J Immunol 143: 2514-2519, 1989. (Pubitemid 19260057)
51. Lin G, Wang J, Lao X, et al: Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother 35: 337-343, 2012.